Ultragenyx Pharmaceutical Inc.
- FDA Approves Dojolvi (triheptanoin) for the Treatment of Long-Chain Fatty Acid Oxidation Disorders - June 30, 2020
- Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO) - June 18, 2020
- Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders - October 14, 2019
- FDA Approves Label Update for Crysvita (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH) in Pediatric Patients 6 Months of Age and Older - September 30, 2019
- Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders - August 1, 2019
- Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019 - November 14, 2018
- FDA Approves Crysvita (burosumab-twza) for X-Linked Hypophosphatemia - April 17, 2018
- FDA Approves Mepsevii (vestronidase alfa) for Mucopolysaccharidosis Type VII - November 15, 2017
- Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab Biologics License Application - October 10, 2017
- Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab Biologics License Application in the US - August 24, 2017
Drugs Associated with Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Generic name: burosumab
Drug class: miscellaneous metabolic agents
Generic name: triheptanoin
Drug class: oral nutritional supplements
Generic name: vestronidase alfa
Drug class: lysosomal enzymes
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|